HIGHLIGHTS
en Cáncer de Colon

ASCO GI 2020

Highlights comentados por:
Dra. Nuria Rodríguez Salas
Servicio de Oncología Médica. Hospital Universitario La Paz, Madrid.
Abstracts relacionados con Aflibercept

Abstracts relacionados con Aflibercept

Efficacy and safety of the combination of aflibercept with fluorouracil, leucovorin, and irinotecan in patients aged 70 years and older with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen in Spain: A retrospective multicenter cohort study.

Cáncer colorrectal (CCR) localizado

Cáncer colorrectal (CCR) localizado

Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with mFOLFOX6 (three versus six months) in the prospective IDEA France cohort study (PRODIGE-GERCOR).

Cirugía

Cirugía

A randomized phase III trial comparing primary tumor resection plus chemotherapy with chemotherapy alone in incurable stage IV colorectal cancer: JCOG1007 study (iPACS).

Nuevas estrategias de tratamiento

Nuevas estrategias de tratamiento

Encorafenib plus cetuximab with or without binimetinib for BRAF V600E-mutant metastatic colorectal cancer: Quality-of-life results from a randomized, three-arm, phase III study versus the choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC).

Estrategias de inmunoterapia

Estrategias de inmunoterapia

Nivolumab plus low-dose ipilimumab as first-line therapy in microsatellite instability-high/DNA mismatch repair deficient metastatic colorectal cancer: Clinical update.

Biopsia líquida

Biopsia líquida

Utility of circulating tumor DNA (ctDNA) versus tumor tissue clinical sequencing for enrolling patients (Pts) with advanced gastrointestinal (GI) cancer to matched clinical trials: SCRUM-Japan GI-SCREEN and GOZILA Combined Analysis.